Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa

An analysis using hepatitis C virus as a proxy biomarker

Yousra A. Mohamoud, F. DeWolfe Miller, Laith Aburaddad

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The Middle East and North Africa (MENA) region has endured several major events of infection parenteral transmission. Recent work has established the utility of using hepatitis C virus (HCV) as a proxy biomarker for assessing the epidemic potential for human immunodeficiency virus (HIV) parenteral transmission. In this review, we use data on the prevalence of HCV infection antibody (seroprevalence) among general population and high risk population groups to assess the potential for HIV parenteral transmission in MENA. Relatively low prevalence of HCV infection in the general population groups was reported in most MENA countries indicating that parenteral HIV transmission at endemic levels does not appear to be a cause for concern. Nonetheless, there could be opportunities for localized HIV outbreaks and transmission of other blood-borne infections in some settings such as healthcare facilities. Though there have been steady improvements in safety measures related to parenteral modes of transmission in the region, these improvements have not been uniform across all countries. More precautions, including infection control training programs, surveillance systems for nosocomial infections and wider coverage and evaluation of hepatitis B virus immunization programs need to be implemented to avoid the unnecessary spread of HIV, HCV, and other blood-borne pathogens along the parenteral modes of transmission.

Original languageEnglish
Pages (from-to)12734-12752
Number of pages19
JournalWorld Journal of Gastroenterology
Volume20
Issue number36
DOIs
Publication statusPublished - 28 Sep 2014
Externally publishedYes

Fingerprint

Northern Africa
Eastern Africa
Middle East
Proxy
Hepacivirus
Biomarkers
HIV
Virus Diseases
Population Groups
Blood-Borne Pathogens
Immunization Programs
Infectious Disease Transmission
Hepatitis C Antibodies
Seroepidemiologic Studies
Infection Control
Cross Infection
Hepatitis B virus
Disease Outbreaks
Delivery of Health Care
Safety

Keywords

  • Hepatitis C virus
  • Human immunodeficiency virus
  • Middle East and North Africa
  • Parenteral transmission
  • Proxy biomarker

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa : An analysis using hepatitis C virus as a proxy biomarker. / Mohamoud, Yousra A.; Miller, F. DeWolfe; Aburaddad, Laith.

In: World Journal of Gastroenterology, Vol. 20, No. 36, 28.09.2014, p. 12734-12752.

Research output: Contribution to journalReview article

@article{657be789b9bb4b5a8c3dbc6448aa419f,
title = "Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: An analysis using hepatitis C virus as a proxy biomarker",
abstract = "The Middle East and North Africa (MENA) region has endured several major events of infection parenteral transmission. Recent work has established the utility of using hepatitis C virus (HCV) as a proxy biomarker for assessing the epidemic potential for human immunodeficiency virus (HIV) parenteral transmission. In this review, we use data on the prevalence of HCV infection antibody (seroprevalence) among general population and high risk population groups to assess the potential for HIV parenteral transmission in MENA. Relatively low prevalence of HCV infection in the general population groups was reported in most MENA countries indicating that parenteral HIV transmission at endemic levels does not appear to be a cause for concern. Nonetheless, there could be opportunities for localized HIV outbreaks and transmission of other blood-borne infections in some settings such as healthcare facilities. Though there have been steady improvements in safety measures related to parenteral modes of transmission in the region, these improvements have not been uniform across all countries. More precautions, including infection control training programs, surveillance systems for nosocomial infections and wider coverage and evaluation of hepatitis B virus immunization programs need to be implemented to avoid the unnecessary spread of HIV, HCV, and other blood-borne pathogens along the parenteral modes of transmission.",
keywords = "Hepatitis C virus, Human immunodeficiency virus, Middle East and North Africa, Parenteral transmission, Proxy biomarker",
author = "Mohamoud, {Yousra A.} and Miller, {F. DeWolfe} and Laith Aburaddad",
year = "2014",
month = "9",
day = "28",
doi = "10.3748/wjg.v20.i36.12734",
language = "English",
volume = "20",
pages = "12734--12752",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

TY - JOUR

T1 - Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa

T2 - An analysis using hepatitis C virus as a proxy biomarker

AU - Mohamoud, Yousra A.

AU - Miller, F. DeWolfe

AU - Aburaddad, Laith

PY - 2014/9/28

Y1 - 2014/9/28

N2 - The Middle East and North Africa (MENA) region has endured several major events of infection parenteral transmission. Recent work has established the utility of using hepatitis C virus (HCV) as a proxy biomarker for assessing the epidemic potential for human immunodeficiency virus (HIV) parenteral transmission. In this review, we use data on the prevalence of HCV infection antibody (seroprevalence) among general population and high risk population groups to assess the potential for HIV parenteral transmission in MENA. Relatively low prevalence of HCV infection in the general population groups was reported in most MENA countries indicating that parenteral HIV transmission at endemic levels does not appear to be a cause for concern. Nonetheless, there could be opportunities for localized HIV outbreaks and transmission of other blood-borne infections in some settings such as healthcare facilities. Though there have been steady improvements in safety measures related to parenteral modes of transmission in the region, these improvements have not been uniform across all countries. More precautions, including infection control training programs, surveillance systems for nosocomial infections and wider coverage and evaluation of hepatitis B virus immunization programs need to be implemented to avoid the unnecessary spread of HIV, HCV, and other blood-borne pathogens along the parenteral modes of transmission.

AB - The Middle East and North Africa (MENA) region has endured several major events of infection parenteral transmission. Recent work has established the utility of using hepatitis C virus (HCV) as a proxy biomarker for assessing the epidemic potential for human immunodeficiency virus (HIV) parenteral transmission. In this review, we use data on the prevalence of HCV infection antibody (seroprevalence) among general population and high risk population groups to assess the potential for HIV parenteral transmission in MENA. Relatively low prevalence of HCV infection in the general population groups was reported in most MENA countries indicating that parenteral HIV transmission at endemic levels does not appear to be a cause for concern. Nonetheless, there could be opportunities for localized HIV outbreaks and transmission of other blood-borne infections in some settings such as healthcare facilities. Though there have been steady improvements in safety measures related to parenteral modes of transmission in the region, these improvements have not been uniform across all countries. More precautions, including infection control training programs, surveillance systems for nosocomial infections and wider coverage and evaluation of hepatitis B virus immunization programs need to be implemented to avoid the unnecessary spread of HIV, HCV, and other blood-borne pathogens along the parenteral modes of transmission.

KW - Hepatitis C virus

KW - Human immunodeficiency virus

KW - Middle East and North Africa

KW - Parenteral transmission

KW - Proxy biomarker

UR - http://www.scopus.com/inward/record.url?scp=84928413003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928413003&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i36.12734

DO - 10.3748/wjg.v20.i36.12734

M3 - Review article

VL - 20

SP - 12734

EP - 12752

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -